quantisnow
FeedTopReportsPricing
⌘K
Live feed
10:03:41·758d
NEWSRelease
Harpoon Therapeutics Inc. logo

Oppenheimer Maintains Outperform on Harpoon Therapeuticsto Outperform

HARP· Harpoon Therapeutics Inc.
Health Care
Original source

Companies

  • HARP
    Harpoon Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jan 5UpdateOppenheimer$23.00
  • Nov 20UpdateTD Cowen-
  • Jul 6UpdateCanaccord Genuity$16.00
  • Nov 11UpdateSVB Leerink$19.00
  • Sep 28UpdateCitigroup$16.00
  • Aug 6UpdateSVB Leerink$25.00

Related

  • PR578d
    Seismic Therapeutic Appoints Julie Eastland as Independent Board Director
  • SEC763d
    SEC Form 15-12G filed by Harpoon Therapeutics Inc.
  • 13D/G766d
    SEC Form SC 13G filed by Harpoon Therapeutics Inc.
  • 13D/G771d
    SEC Form SC 13D/A filed by Harpoon Therapeutics Inc. (Amendment)
  • SEC773d
    SEC Form EFFECT filed by Harpoon Therapeutics Inc.
  • SEC773d
    SEC Form EFFECT filed by Harpoon Therapeutics Inc.
  • SEC773d
    SEC Form EFFECT filed by Harpoon Therapeutics Inc.
  • INSIDER773d
    New Leaf Biopharma Opportunities Ii, L.P. returned 1,859,169 shares to the company and returned 10,000 units of 8.000% Series A Redeemable Preferred Stock to the company (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022